• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,368
2,297
1,863
1,846
1,724

COUNTRY

872
646
269
253
211

CATEGORIES

  • 858
  • 187
  • 678
  • 1,126
    • 99
  • 389
  • 270
  • 252
  • 65
  • 378
  • 688
  • 1,320
  • 1,354
  • 625
  • 884
  • 1,690
  • 2,672
    • 574
    • 118
    • 550
    • 75
    • 526
    • 43
    • 505
    • 18
    • 18
    • 23
  • 507
  • 730
  • 0
  • 93

PRICE

6,753
11,392
17,841
25,099

PUBLISHED

1,958
2,815
7,348
25,099

PRODUCT TYPE

20,978
2,901
870
164
74
44
21
21
19
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2022

EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2022 Summary Atopic dermatitis or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes....

June 2013
FROM

Metastatic Breast Cancer - Pipeline Review, H1 2013

Metastatic Breast Cancer – Pipeline Review, H1 2013 Summary 'Metastatic Breast Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides...

June 2013
FROM

Thalassemia - Pipeline Review, H1 2013

Thalassemia – Pipeline Review, H1 2013 Summary 'Thalassemia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic...

June 2013
FROM

Reperfusion Injury - Pipeline Review, H1 2013

'Reperfusion Injury - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Reperfusion Injury,...

June 2013
FROM

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2013

Chemotherapy Induced Neutropenia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Neutropenia - Pipeline Review, H1 2013', provides an overview of the indication’s...

June 2013
FROM

Diabetic Neuropathic Pain - Pipeline Review, H1 2013

'Diabetic Neuropathic Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Diabetic Neuropathic...

June 2013
FROM

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2013

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2013', provides...

June 2013
FROM

Cardiovascular Disease - Pipeline Review, H1 2013

Cardiovascular Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cardiovascular Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

June 2013
FROM

PharmaPoint: Dermatophytic Onychomycosis (DO) - Current and Future Players

PharmaPoint: Dermatophytic Onychomycosis (DO) - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Dermatophytic Onychomycosis (DO) - Current and Future Players”....

June 2013
FROM

2013 Italy Procedure Volumes Database

This in-depth procedure volumes database quantifies current and forecast (2010-2017) procedure volumes across a spectrum of medical segments in some of the most promising and emerging markets Extensive...

June 2013
FROM

Slovenia Pharmaceuticals and Healthcare Report Q3 2013

BMI View: State-run insurers in Central and Eastern Europe are coming under increasing pressure to manage deficits as revenues decrease and liabilities rise on the back of ageing populations and increased...

June 2013

Finland Pharmaceuticals and Healthcare Report Q3 2013

BMI View: The Finnish government's focus on drug pricing will significantly constrict drugmakers' revenue-earning opportunities in 2013. In addition to the introduction of a reference price system in...

June 2013

Greece Pharmaceuticals and Healthcare Report Q3 2013

BMI View: The Greek pharmaceutical market will continue to be characterised by mandated price reductions, state intervention in pharmaceutical trade and regressive revenue taxes. Although there have...

June 2013

Ukraine Pharmaceuticals and Healthcare Report Q3 2013

BMI View: While we retain a bullish view on the long-term growth prospects of the Ukrainian pharmaceutical market, there remain many aspects of regulation and market access that must be resolved in...

June 2013

Iraq Pharmaceuticals and Healthcare Report Q3 2013

BMI View: Iraq's economy is one of the fastest growing in the region, and increased revenues from oil ensure that the government will have funds to dedicate to improving healthcare services. The primary...

June 2013

Thailand Pharmaceuticals and Healthcare Report Q3 2013

BMI View: Despite public sector financial challenges that continue to be posed by the expanding healthcare insurance coverage, we still envisage steady growth in medicine consumption and the use of...

June 2013

Uzbekistan Pharmaceuticals and Healthcare Report Q3 2013

BMI View: We expect interest in Uzbekistan’s pharmaceutical market to increase over the coming decades, both from the point of view of imports and local involvement in drug manufacturing. The government...

June 2013

Cambodia and Laos Pharmaceuticals and Healthcare Report Q3 2013

BMI View: We maintain that significant foreign interest in Cambodia will be unlikely given the lack of proper regulation, rampant corruption and poor infrastructure in the country. In addition, due...

June 2013
Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018 Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018 - Product Thumbnail Image

Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Epigenetics Drugs And Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018 The research report on the epigenetics drugs and diagnostic technologies...

June 2013
FROM
Ariad's AP26113 - second generation ALK inhibitor for NSCLC Ariad's AP26113 - second generation ALK inhibitor for NSCLC - Product Thumbnail Image

Ariad's AP26113 - second generation ALK inhibitor for NSCLC

Ariad Pharmaceuticals is developing AP26113, an orally-administered small-molecule tyrosine kinase inhibitor with activity against the anaplastic lymphoma kinase (ALK) fusion and its resistant forms,...

June 2013
FROM
Loading Indicator

Our Clients

Our clients' logos